Report Cover

United States Generic Drugs Market Report & Forecast 2021-2027


United States Generic Drugs Market, By Type, 2016-2021, 2022-2027 ($ Millions)
United States Generic Drugs Market Segment Percentages, By Type, 2020 (%)
    Prescription
    Non-Prescription Drugs

United States Generic Drugs Market, By Application, 2016-2021, 2022-2027 ($ Millions)
United States Generic Drugs Market Segment Percentages, By Application, 2020 (%)
    Hospital
    Clinic
    Others

Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Generic Drugs revenues in United States market, 2016-2021 (Estimated), ($ millions)
Key companies Generic Drugs revenues share in United States market, 2020 (%)
Further, the report presents profiles of competitors in the market, key players include:
    Teva
    Novartis - Sandoz
    Mylan
    Sun Pharmaceutical
    Aspen
    Fresenius Kabi
    Pfizer (Hospira)
    Sanofi
    Aurobindo
    Lupin
    Dr. Reddy's
    Apotex
    Cipla
    ENDO (Par Pharmaceutical)
    Stada Arzneimittel
    Krka Group
    Nichi-Iko Pharmaceutical
    Valeant
    Zydus Cadila
    Hikma
    Pharmaniaga Berhad
    Hovid Berhad
    Duopharma Biotech
    Kotra Pharma
    HOE Pharmaceutical
    Y.S.P. Industries
1 Introduction to Research & Analysis Reports
    1.1 Generic Drugs Market Definition
    1.2 Market Segments
        1.2.1 Segment by Type
        1.2.2 Segment by Application
    1.3 United States Generic Drugs Market Overview
    1.4 Methodology & Sources of Information
        1.4.1 Research Methodology
        1.4.2 Research Process
        1.4.3 Base Year

2 United States Generic Drugs Overall Market Size
    2.1 United States Generic Drugs Market Size: 2021 VS 2027
    2.2 United States Generic Drugs Revenue, Prospects & Forecasts: 2016-2027
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints

3 Company Landscape
    3.1 Top Generic Drugs Players in United States Market
    3.2 Top United States Generic Drugs Companies Ranked by Revenue
    3.3 United States Generic Drugs Revenue by Companies
    3.4 Top 3 and Top 5 Generic Drugs Companies in United States Market, by Revenue in 2020
    3.5 Companies Generic Drugs Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Generic Drugs Players in United States Market
        3.6.1 List of Tier 1 Generic Drugs Companies in United States
        3.6.2 List of Tier 2 and Tier 3 Generic Drugs Companies in United States

4 Sights by Type
    4.1 Overview
        4.1.1 By Type - United States Generic Drugs Market Size Markets, 2021 & 2027
        4.1.2 Prescription
        4.1.3 Non-Prescription Drugs
    4.2 By Type - United States Generic Drugs Revenue & Forecasts
        4.2.1 By Type - United States Generic Drugs Revenue, 2016-2021
        4.2.2 By Type - United States Generic Drugs Revenue, 2022-2027
        4.2.3 By Type - United States Generic Drugs Revenue Market Share, 2016-2027

5 Sights by Application
    5.1 Overview
        5.1.1 By Application - United States Generic Drugs Market Size, 2021 & 2027
        5.1.2 Hospital
        5.1.3 Clinic
        5.1.4 Others
    5.2 By Application - United States Generic Drugs Revenue & Forecasts
        5.2.1 By Application - United States Generic Drugs Revenue, 2016-2021
        5.2.2 By Application - United States Generic Drugs Revenue, 2022-2027
        5.2.3 By Application - United States Generic Drugs Revenue Market Share, 2016-2027

6 Generic Drugs Companies Profiles
    6.1 Teva
        6.1.1 Teva Company Details
        6.1.2 Teva Business Overview
        6.1.3 Teva Generic Drugs Introduction
        6.1.4 Teva Generic Drugs Revenue in United States Market (2016-2021)
        6.1.5 Teva Recent Developments
    6.2 Novartis - Sandoz
        6.2.1 Novartis - Sandoz Company Details
        6.2.2 Novartis - Sandoz Business Overview
        6.2.3 Novartis - Sandoz Generic Drugs Introduction
        6.2.4 Novartis - Sandoz Generic Drugs Revenue in United States Market (2016-2021)
        6.2.5 Novartis - Sandoz Recent Developments
    6.3 Mylan
        6.3.1 Mylan Company Details
        6.3.2 Mylan Business Overview
        6.3.3 Mylan Generic Drugs Introduction
        6.3.4 Mylan Generic Drugs Revenue in United States Market (2016-2021)
        6.3.5 Mylan Recent Developments
    6.4 Sun Pharmaceutical
        6.4.1 Sun Pharmaceutical Company Details
        6.4.2 Sun Pharmaceutical Business Overview
        6.4.3 Sun Pharmaceutical Generic Drugs Introduction
        6.4.4 Sun Pharmaceutical Generic Drugs Revenue in United States Market (2016-2021)
        6.4.5 Sun Pharmaceutical Recent Developments
    6.5 Aspen
        6.5.1 Aspen Company Details
        6.5.2 Aspen Business Overview
        6.5.3 Aspen Generic Drugs Introduction
        6.5.4 Aspen Generic Drugs Revenue in United States Market (2016-2021)
        6.5.5 Aspen Recent Developments
    6.6 Fresenius Kabi
        6.6.1 Fresenius Kabi Company Details
        6.6.2 Fresenius Kabi Business Overview
        6.6.3 Fresenius Kabi Generic Drugs Introduction
        6.6.4 Fresenius Kabi Generic Drugs Revenue in United States Market (2016-2021)
        6.6.5 Fresenius Kabi Recent Developments
    6.7 Pfizer (Hospira)
        6.7.1 Pfizer (Hospira) Company Details
        6.7.2 Pfizer (Hospira) Business Overview
        6.7.3 Pfizer (Hospira) Generic Drugs Introduction
        6.7.4 Pfizer (Hospira) Generic Drugs Revenue in United States Market (2016-2021)
        6.7.5 Pfizer (Hospira) Recent Developments
    6.8 Sanofi
        6.8.1 Sanofi Company Details
        6.8.2 Sanofi Business Overview
        6.8.3 Sanofi Generic Drugs Introduction
        6.8.4 Sanofi Generic Drugs Revenue in United States Market (2016-2021)
        6.8.5 Sanofi Recent Developments
    6.9 Aurobindo
        6.9.1 Aurobindo Company Details
        6.9.2 Aurobindo Business Overview
        6.9.3 Aurobindo Generic Drugs Introduction
        6.9.4 Aurobindo Generic Drugs Revenue in United States Market (2016-2021)
        6.9.5 Aurobindo Recent Developments
    6.10 Lupin
        6.10.1 Lupin Company Details
        6.10.2 Lupin Business Overview
        6.10.3 Lupin Generic Drugs Introduction
        6.10.4 Lupin Generic Drugs Revenue in United States Market (2016-2021)
        6.10.5 Lupin Recent Developments
    6.11 Dr. Reddy's
        6.11.1 Dr. Reddy's Company Details
        6.11.2 Dr. Reddy's Business Overview
        6.11.3 Dr. Reddy's Generic Drugs Introduction
        6.11.4 Dr. Reddy's Generic Drugs Revenue in United States Market (2016-2021)
        6.11.5 Dr. Reddy's Recent Developments
    6.12 Apotex
        6.12.1 Apotex Company Details
        6.12.2 Apotex Business Overview
        6.12.3 Apotex Generic Drugs Introduction
        6.12.4 Apotex Generic Drugs Revenue in United States Market (2016-2021)
        6.12.5 Apotex Recent Developments
    6.13 Cipla
        6.13.1 Cipla Company Details
        6.13.2 Cipla Business Overview
        6.13.3 Cipla Generic Drugs Introduction
        6.13.4 Cipla Generic Drugs Revenue in United States Market (2016-2021)
        6.13.5 Cipla Recent Developments
    6.14 ENDO (Par Pharmaceutical)
        6.14.1 ENDO (Par Pharmaceutical) Company Details
        6.14.2 ENDO (Par Pharmaceutical) Business Overview
        6.14.3 ENDO (Par Pharmaceutical) Generic Drugs Introduction
        6.14.4 ENDO (Par Pharmaceutical) Generic Drugs Revenue in United States Market (2016-2021)
        6.14.5 ENDO (Par Pharmaceutical) Recent Developments
    6.15 Stada Arzneimittel
        6.15.1 Stada Arzneimittel Company Details
        6.15.2 Stada Arzneimittel Business Overview
        6.15.3 Stada Arzneimittel Generic Drugs Introduction
        6.15.4 Stada Arzneimittel Generic Drugs Revenue in United States Market (2016-2021)
        6.15.5 Stada Arzneimittel Recent Developments
    6.16 Krka Group
        6.16.1 Krka Group Company Details
        6.16.2 Krka Group Business Overview
        6.16.3 Krka Group Generic Drugs Introduction
        6.16.4 Krka Group Generic Drugs Revenue in United States Market (2016-2021)
        6.16.5 Krka Group Recent Developments
    6.17 Nichi-Iko Pharmaceutical
        6.17.1 Nichi-Iko Pharmaceutical Company Details
        6.17.2 Nichi-Iko Pharmaceutical Business Overview
        6.17.3 Nichi-Iko Pharmaceutical Generic Drugs Introduction
        6.17.4 Nichi-Iko Pharmaceutical Generic Drugs Revenue in United States Market (2016-2021)
        6.17.5 Nichi-Iko Pharmaceutical Recent Developments
    6.18 Valeant
        6.18.1 Valeant Company Details
        6.18.2 Valeant Business Overview
        6.18.3 Valeant Generic Drugs Introduction
        6.18.4 Valeant Generic Drugs Revenue in United States Market (2016-2021)
        6.18.5 Valeant Recent Developments
    6.19 Zydus Cadila
        6.19.1 Zydus Cadila Company Details
        6.19.2 Zydus Cadila Business Overview
        6.19.3 Zydus Cadila Generic Drugs Introduction
        6.19.4 Zydus Cadila Generic Drugs Revenue in United States Market (2016-2021)
        6.19.5 Zydus Cadila Recent Developments
    6.20 Hikma
        6.20.1 Hikma Company Details
        6.20.2 Hikma Business Overview
        6.20.3 Hikma Generic Drugs Introduction
        6.20.4 Hikma Generic Drugs Revenue in United States Market (2016-2021)
        6.20.5 Hikma Recent Developments
    6.21 Pharmaniaga Berhad
        6.21.1 Pharmaniaga Berhad Company Details
        6.21.2 Pharmaniaga Berhad Business Overview
        6.21.3 Pharmaniaga Berhad Generic Drugs Introduction
        6.21.4 Pharmaniaga Berhad Generic Drugs Revenue in United States Market (2016-2021)
        6.21.5 Pharmaniaga Berhad Recent Developments
    6.22 Hovid Berhad
        6.22.1 Hovid Berhad Company Details
        6.22.2 Hovid Berhad Business Overview
        6.22.3 Hovid Berhad Generic Drugs Introduction
        6.22.4 Hovid Berhad Generic Drugs Revenue in United States Market (2016-2021)
        6.22.5 Hovid Berhad Recent Developments
    6.23 Duopharma Biotech
        6.23.1 Duopharma Biotech Company Details
        6.23.2 Duopharma Biotech Business Overview
        6.23.3 Duopharma Biotech Generic Drugs Introduction
        6.23.4 Duopharma Biotech Generic Drugs Revenue in United States Market (2016-2021)
        6.23.5 Duopharma Biotech Recent Developments
    6.24 Kotra Pharma
        6.24.1 Kotra Pharma Company Details
        6.24.2 Kotra Pharma Business Overview
        6.24.3 Kotra Pharma Generic Drugs Introduction
        6.24.4 Kotra Pharma Generic Drugs Revenue in United States Market (2016-2021)
        6.24.5 Kotra Pharma Recent Developments
    6.25 HOE Pharmaceutical
        6.25.1 HOE Pharmaceutical Company Details
        6.25.2 HOE Pharmaceutical Business Overview
        6.25.3 HOE Pharmaceutical Generic Drugs Introduction
        6.25.4 HOE Pharmaceutical Generic Drugs Revenue in United States Market (2016-2021)
        6.25.5 HOE Pharmaceutical Recent Developments
    6.26 Y.S.P. Industries
        6.26.1 Y.S.P. Industries Company Details
        6.26.2 Y.S.P. Industries Business Overview
        6.26.3 Y.S.P. Industries Generic Drugs Introduction
        6.26.4 Y.S.P. Industries Generic Drugs Revenue in United States Market (2016-2021)
        6.26.5 Y.S.P. Industries Recent Developments

7 Conclusion
8 Appendix
    8.1 Note
    8.2 Examples of Clients
    8.3 Author Details
    8.4 Disclaimer

List of Tables Table 1. Generic Drugs Market Opportunities & Trends in United States Market Table 2. Generic Drugs Market Drivers in United States Market Table 3. Generic Drugs Market Restraints in United States Market Table 4. Key Players of Generic Drugs in United States Market Table 5. Top Generic Drugs Players in United States Market, Ranking by Revenue (2019) Table 6. United States Generic Drugs Revenue by Companies, (US$, Mn), 2016-2021 Table 7. United States Generic Drugs Revenue Share by Companies, 2016-2021 Table 8. Companies Generic Drugs Product Type Table 9. List of Tier 1 Generic Drugs Companies, Revenue (US$, Mn) in 2020 and Market Share Table 10. List of Tier 2 and Tier 3 Generic Drugs Companies, Revenue (US$, Mn) in 2020 and Market Share Table 11. By Type - United States Generic Drugs Revenue, (US$, Mn), 2021 & 2027 Table 12. By Type - United States Generic Drugs Revenue (US$, Mn), 2016-2021 Table 13. By Type - United States Generic Drugs Revenue (US$, Mn), 2022-2027 Table 14. By Application - United States Generic Drugs Revenue, (US$, Mn), 2021 VS 2027 Table 15. By Application - United States Generic Drugs Revenue (US$, Mn), 2016-2021 Table 16. By Application - United States Generic Drugs Revenue (US$, Mn), 2022-2027 Table 17. Teva Company Details Table 18. Teva Business Overview Table 19. Teva Generic Drugs Product Table 20. Teva Generic Drugs Revenue in United States Market (2016-2021) & (US$ Million) Table 21. Teva Recent Developments Table 22. Novartis - Sandoz Company Details Table 23. Novartis - Sandoz Business Overview Table 24. Novartis - Sandoz Generic Drugs Product Table 25. Novartis - Sandoz Generic Drugs Revenue in United States Market (2016-2021) & (US$ Million) Table 26. Novartis - Sandoz Recent Developments Table 27. Mylan Company Details Table 28. Mylan Business Overview Table 29. Mylan Generic Drugs Product Table 30. Mylan Generic Drugs Revenue in United States Market (2016-2021) & (US$ Million) Table 31. Mylan Recent Developments Table 32. Sun Pharmaceutical Company Details Table 33. Sun Pharmaceutical Business Overview Table 34. Sun Pharmaceutical Generic Drugs Product Table 35. Sun Pharmaceutical Generic Drugs Revenue in United States Market (2016-2021) & (US$ Million) Table 36. Sun Pharmaceutical Recent Developments Table 37. Aspen Company Details Table 38. Aspen Business Overview Table 39. Aspen Generic Drugs Product Table 40. Aspen Generic Drugs Revenue in United States Market (2016-2021) & (US$ Million) Table 41. Aspen Recent Developments Table 42. Fresenius Kabi Company Details Table 43. Fresenius Kabi Business Overview Table 44. Fresenius Kabi Generic Drugs Product Table 45. Fresenius Kabi Generic Drugs Revenue in United States Market (2016-2021) & (US$ Million) Table 46. Fresenius Kabi Recent Developments Table 47. Pfizer (Hospira) Company Details Table 48. Pfizer (Hospira) Business Overview Table 49. Pfizer (Hospira) Generic Drugs Product Table 50. Pfizer (Hospira) Generic Drugs Revenue in United States Market (2016-2021) & (US$ Million) Table 51. Pfizer (Hospira) Recent Developments Table 52. Sanofi Company Details Table 53. Sanofi Business Overview Table 54. Sanofi Generic Drugs Product Table 55. Sanofi Generic Drugs Revenue in United States Market (2016-2021) & (US$ Million) Table 56. Sanofi Recent Developments Table 57. Aurobindo Company Details Table 58. Aurobindo Business Overview Table 59. Aurobindo Generic Drugs Product Table 60. Aurobindo Generic Drugs Revenue in United States Market (2016-2021) & (US$ Million) Table 61. Aurobindo Recent Developments Table 62. Lupin Company Details Table 63. Lupin Business Overview Table 64. Lupin Generic Drugs Product Table 65. Lupin Generic Drugs Revenue in United States Market (2016-2021) & (US$ Million) Table 66. Lupin Recent Developments Table 67. Dr. Reddy's Company Details Table 68. Dr. Reddy's Business Overview Table 69. Dr. Reddy's Generic Drugs Product Table 70. Dr. Reddy's Generic Drugs Revenue in United States Market (2016-2021) & (US$ Million) Table 71. Dr. Reddy's Recent Developments Table 72. Apotex Company Details Table 73. Apotex Business Overview Table 74. Apotex Generic Drugs Product Table 75. Apotex Generic Drugs Revenue in United States Market (2016-2021) & (US$ Million) Table 76. Apotex Recent Developments Table 77. Cipla Company Details Table 78. Cipla Business Overview Table 79. Cipla Generic Drugs Product Table 80. Cipla Generic Drugs Revenue in United States Market (2016-2021) & (US$ Million) Table 81. Cipla Recent Developments Table 82. ENDO (Par Pharmaceutical) Company Details Table 83. ENDO (Par Pharmaceutical) Business Overview Table 84. ENDO (Par Pharmaceutical) Generic Drugs Product Table 85. ENDO (Par Pharmaceutical) Generic Drugs Revenue in United States Market (2016-2021) & (US$ Million) Table 86. ENDO (Par Pharmaceutical) Recent Developments Table 87. Stada Arzneimittel Business Overview Table 88. Stada Arzneimittel Company Details Table 89. Stada Arzneimittel Generic Drugs Product Table 90. Stada Arzneimittel Generic Drugs Revenue in United States Market (2016-2021) & (US$ Million) Table 91. Stada Arzneimittel Recent Developments Table 92. Krka Group Company Details Table 93. Krka Group Business Overview Table 94. Krka Group Generic Drugs Product Table 95. Krka Group Generic Drugs Revenue in United States Market (2016-2021) & (US$ Million) Table 96. Krka Group Recent Developments Table 97. Nichi-Iko Pharmaceutical Company Details Table 98. Nichi-Iko Pharmaceutical Business Overview Table 99. Nichi-Iko Pharmaceutical Generic Drugs Product Table 100. Nichi-Iko Pharmaceutical Generic Drugs Revenue in United States Market (2016-2021) & (US$ Million) Table 101. Nichi-Iko Pharmaceutical Recent Developments Table 102. Valeant Company Details Table 103. Valeant Business Overview Table 104. Valeant Generic Drugs Product Table 105. Valeant Generic Drugs Revenue in United States Market (2016-2021) & (US$ Million) Table 106. Valeant Recent Developments Table 107. Zydus Cadila Company Details Table 108. Zydus Cadila Business Overview Table 109. Zydus Cadila Generic Drugs Product Table 110. Zydus Cadila Generic Drugs Revenue in United States Market (2016-2021) & (US$ Million) Table 111. Zydus Cadila Recent Developments Table 112. Hikma Company Details Table 113. Hikma Business Overview Table 114. Hikma Generic Drugs Product Table 115. Hikma Generic Drugs Revenue in United States Market (2016-2021) & (US$ Million) Table 116. Hikma Recent Developments Table 117. Pharmaniaga Berhad Company Details Table 118. Pharmaniaga Berhad Business Overview Table 119. Pharmaniaga Berhad Generic Drugs Product Table 120. Pharmaniaga Berhad Generic Drugs Revenue in United States Market (2016-2021) & (US$ Million) Table 121. Pharmaniaga Berhad Recent Developments Table 122. Hovid Berhad Company Details Table 123. Hovid Berhad Business Overview Table 124. Hovid Berhad Generic Drugs Product Table 125. Hovid Berhad Generic Drugs Revenue in United States Market (2016-2021) & (US$ Million) Table 126. Hovid Berhad Recent Developments Table 127. Duopharma Biotech Company Details Table 128. Duopharma Biotech Business Overview Table 129. Duopharma Biotech Generic Drugs Product Table 130. Duopharma Biotech Generic Drugs Revenue in United States Market (2016-2021) & (US$ Million) Table 131. Duopharma Biotech Recent Developments Table 132. Kotra Pharma Company Details Table 133. Kotra Pharma Business Overview Table 134. Kotra Pharma Generic Drugs Product Table 135. Kotra Pharma Generic Drugs Revenue in United States Market (2016-2021) & (US$ Million) Table 136. Kotra Pharma Recent Developments Table 137. HOE Pharmaceutical Company Details Table 138. HOE Pharmaceutical Business Overview Table 139. HOE Pharmaceutical Generic Drugs Product Table 140. HOE Pharmaceutical Generic Drugs Revenue in United States Market (2016-2021) & (US$ Million) Table 141. HOE Pharmaceutical Recent Developments Table 142. Y.S.P. Industries Company Details Table 143. Y.S.P. Industries Business Overview Table 144. Y.S.P. Industries Generic Drugs Product Table 145. Y.S.P. Industries Generic Drugs Revenue in United States Market (2016-2021) & (US$ Million) Table 146. Y.S.P. Industries Recent Developments List of Figures Figure 1. Generic Drugs Segment by Type Figure 2. Generic Drugs Segment by Application Figure 3. United States Generic Drugs Market Overview: 2020 Figure 4. United States Generic Drugs Market Size: 2021 VS 2027 (US$, Mn) Figure 5. United States Generic Drugs Revenue, 2016-2027 (US$, Mn) Figure 6. The Top 3 and 5 Players Market Share by Generic Drugs Revenue in 2020 Figure 7. By Type - United States Generic Drugs Revenue Market Share, 2016-2027 Figure 8. By Application - United States Generic Drugs Revenue Market Share, 2016-2027 Figure 9. Teva Generic Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 10. Novartis - Sandoz Generic Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 11. Mylan Generic Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 12. Sun Pharmaceutical Generic Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 13. Aspen Generic Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 14. Fresenius Kabi Generic Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 15. Pfizer (Hospira) Generic Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 16. Sanofi Generic Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 17. Aurobindo Generic Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 18. Lupin Generic Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 19. Dr. Reddy's Generic Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 20. Apotex Generic Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 21. Cipla Generic Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 22. ENDO (Par Pharmaceutical) Generic Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 23. Stada Arzneimittel Generic Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 24. Krka Group Generic Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 25. Nichi-Iko Pharmaceutical Generic Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 26. Valeant Generic Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 27. Zydus Cadila Generic Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 28. Hikma Generic Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 29. Pharmaniaga Berhad Generic Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 30. Hovid Berhad Generic Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 31. Duopharma Biotech Generic Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 32. Kotra Pharma Generic Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 33. HOE Pharmaceutical Generic Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 34. Y.S.P. Industries Generic Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)

This research study involved the extensive usage of both primary and secondary data sources.  The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. Top-down and bottom-up approaches are used to validate the global market size market and estimate the market size for manufacturers, regions segments, product segments and applications (end users). All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from QYResearch and presented in this report.
 

After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
 

Secondary Sources occupies Approximately 25% of Sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on; This research study involved the usage of widespread secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; BIS Statistics; ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the Light Aircraft market. It was also used to obtain important information about the top players, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.
 

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers etc.
 

The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
 

Primary research was conducted to identify segmentation types, product price range, product applications, key players, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.
 

Publisher: QY Research
Chat with us